Table 1 Patients and clinical outcomes with dasatinib monotherapy
No | Age | Sex | Dasatinib dose | BM relapse | BCR-ABL mutation | EFS, day | Outcome / Event (cause of death) |
|---|---|---|---|---|---|---|---|
1 | 56 | M | 100 mg QD | No | No | 624* | SCT in CMR |
2 | 56 | M | 100 mg QD | No | No | 149 | dead (infection) |
3 | 64 | F | 100 mg QD | No | No | 318 | CMR |
4 | 68 | M | 100 mg QD | Yes | T315I | 368 | dead (PD) |
5 | 67 | F | 100 mg QD | Yes | T315I | 197 | dead (PD) |
6 | 22 | F | 100 mg QD | No | No | 634* | SCT in CMR |
7 | 77 | M | 50 mg BID | Yes | T315I | 221 | dead (PD) |
8 | 63 | F | 50 mg QD | Yes | T315I | 106 | dead (PD) |
9 | 80 | F | 100 mg QD | No | No | 269 | CMR |
10 | 32 | M | 100 mg QD | No | No | 158 | CMR |
11 | 78 | M | 100 mg QD | Yes | No | 114 | dead (PD) |